ClinicalTrials.Veeva

Menu

Registry to Collect Health Information Related to Fibrolamellar Cancer

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Active, not recruiting

Conditions

FLC
Fibrolamellar Cancer
Liver Cancer

Treatments

Behavioral: Questionnaire

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to collect information about people with fibrolamellar cancer (FLC). This study is a registry of people with FLC around the world. This study will involve collecting information about participants, their medical history and the regular medical care they receive for FLC. The study will not provide treatment for your cancer.

Enrollment

100 estimated patients

Sex

All

Ages

13+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 13 years or older.

  • Personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)

  • Participants must have access to electronic devices that meet the following minimum requirements:

    • Ability to connect to the internet
    • Capability of running modern internet browers (such as Google Chrome, Internet Explorer, Safari, or Mozilla Firefox).
  • Participants must have a google account

Exclusion criteria

  • Participants residing in the European Union (EU).

Trial design

100 participants in 1 patient group

Participants with Fibrolamellar Carcinoma/FLC
Description:
Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
Treatment:
Behavioral: Questionnaire

Trial contacts and locations

1

Loading...

Central trial contact

Imane El Dika, MD; Ghassan Abou-Alfa, MD, MBA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems